Trial · NCT03110900
Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation
NCT03110900, Phase 4, Terminated, University of Arkansas; results first posted 2018-06-11
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation. Trials, record NCT03110900. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03110900
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation
- NCT number
- NCT03110900
- Status
- Terminated
- Phases
- Phase 4
- Enrollment
- 2 participants, actual
- Lead sponsor
- University of Arkansas
- Conditions
- Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use, Lorazepam Causing Adverse Effects in Therapeutic Use, Loxapine Causing Adverse Effects in Therapeutic Use
- Interventions
- Haloperidol + lorazepam, Loxapine
- First posted
- 2017-04-12
- Last updated
- 2018-06-11
- Results first posted
- 2018-06-11
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Subjects Reporting Reduction of Agitation on Positive and Negative Syndrome Scale (PANSS) | 120 minutes | Change in agitation level on the PANSS from baseline up to 120 minutes -- terminated by sponsor before results available |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Subjects Reporting Reduction of Agitation on Positive and Negative Syndrome Scale (PANSS) | 120 minutes | No data was collected because the sponsor terminated the study before any data could be collected. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Haloperidol + Lorazepam | 1 | |
| Overall Study | STARTED | Loxapine | 1 | |
| Overall Study | COMPLETED | Haloperidol + Lorazepam | 0 | |
| Overall Study | COMPLETED | Loxapine | 0 | |
| Overall Study | NOT COMPLETED | Haloperidol + Lorazepam | 1 | |
| Overall Study | NOT COMPLETED | Loxapine | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Haloperidol + Lorazepam | 0 | 1 |
| Total, all-cause mortality | Loxapine | 0 | 1 |
| Total, other adverse events | Haloperidol + Lorazepam | 0 | 1 |
| Total, other adverse events | Loxapine | 0 | 1 |
| Total, serious adverse events | Haloperidol + Lorazepam | 0 | 1 |
| Total, serious adverse events | Loxapine | 0 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Haloperidol + Lorazepam vs Loxapine: deaths from any cause | Trial comparisons |
| Haloperidol + Lorazepam vs Loxapine: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03110900
GET https://conductscience.org/api/trials/v1/NCT03110900/registered